论文部分内容阅读
目的:观察急性冠状动脉综合征(ACS)患者血浆髓过氧化物酶(MPO)水平与其近期预后的相关性。方法:共入选ACS患者132例,测血浆MPO和心脏肌钙蛋白(cTnT),并对患者进行以缺血性胸痛、再发非致命性心肌梗死、心力衰竭、心血管原因的再住院、心血管原因的死亡为终点事件的30d随访;按cTnT水平分为cTnT无升高组和升高组,继之按MPO水平分别行二分位数分组。结果:cTnT无升高组的ACS患者中,MPO较高亚组(2组)的终点事件发生率明显高于MPO较低亚组(1组),比值比(OR)=8.09,95%置信区间为[1.03,71.87],P<0.05;cTnT升高组的ACS患者中,MPO较高亚组(B组)的终点事件发生率明显高于MPO较低亚组(A组),OR=4.00,95%置信区间为[1.06,16.38],P<0.05。逻辑回归分析表明MPO是ACS患者发生终点事件的危险因素。结论:血浆MPO水平与ACS的近期预后有明显的相关性,是ACS患者发生终点事件的危险因素。
Objective: To investigate the correlation between plasma levels of myeloperoxidase (MPO) and its prognosis in patients with acute coronary syndrome (ACS). Methods: A total of 132 patients with ACS were enrolled in this study. Plasma MPO and cardiac troponin (cTnT) were measured. Patients were followed up with ischemic chest pain, non-fatal myocardial infarction, heart failure, cardiovascular rehospitalization, heart failure The death from vascular causes was followed up for 30 days. According to the level of cTnT, no cTnT or elevated cTnT group was given, followed by the dichotomous group according to MPO level. RESULTS: Among ACS patients without elevation of cTnT, the incidence of endpoint events in the higher MPO subgroups (group 2) was significantly higher than in the lower MPO subgroups (group 1), odds ratio (OR) = 8.09, 95% confidence (1.03,71.87), P <0.05. Among ACS patients with elevated cTnT, the incidence of end point events in the higher MPO subgroup (group B) was significantly higher than that in the lower MPO subgroup (group A), OR = 4.00, 95% confidence interval [1.06, 16.38], P <0.05. Logistic regression analysis showed that MPO was a risk factor for endpoint of ACS. Conclusion: The plasma MPO level has a clear correlation with the short-term prognosis of ACS and is a risk factor for the occurrence of end point in patients with ACS.